Cabenuva (cabotegravir + rilpivirine) vs Sunlenca (lenacapavir)
Cabenuva (cabotegravir + rilpivirine) vs Sunlenca (lenacapavir)
Cabenuva, a combination of cabotegravir and rilpivirine, is an injectable treatment for HIV-1 infection in adults, administered once monthly or every two months after an initial oral dosing phase, and is designed for those who are virologically suppressed on a stable antiretroviral regimen. Sunlenca (lenacapavir) is a long-acting HIV-1 treatment option that works by inhibiting the capsid function, essential for viral replication, and is administered every six months after an initial oral dosing phase, offering an even less frequent dosing schedule. When deciding between the two, patients should consider factors such as dosing frequency, mode of administration, drug resistance profile, and individual medical history in consultation with their healthcare provider.
Difference between Cabenuva and Sunlenca
Metric | Cabenuva (cabotegravir + rilpivirine) | Sunlenca (lenacapavir) |
---|---|---|
Generic name | Cabotegravir, Rilpivirine | Lenacapavir |
Indications | HIV-1 treatment in adults | HIV-1 treatment in adults |
Mechanism of action | Integrase inhibitor (cabotegravir), NNRTI (rilpivirine) | Capsid inhibitor |
Brand names | Cabenuva | Sunlenca |
Administrative route | Intramuscular injection | Subcutaneous, oral |
Side effects | Fever, fatigue, headache, musculoskeletal pain, nausea, sleep disorders, dizziness, rash | Nausea, diarrhea, headache, fatigue, insomnia, muscle pain |
Contraindications | Previous hypersensitivity reaction to cabotegravir or rilpivirine | Previous hypersensitivity reaction to lenacapavir or any component of the formulation |
Drug class | Antiretroviral | Antiretroviral |
Manufacturer | ViiV Healthcare, Janssen | Gilead Sciences |
Efficacy
Efficacy of Cabenuva (cabotegravir + rilpivirine)
Cabenuva is a combination of two antiretroviral medications, cabotegravir and rilpivirine, which is used for the treatment of human immunodeficiency virus (HIV) in adults. Cabenuva is administered as an intramuscular injection once a month or every two months, offering an alternative to daily oral HIV medications. Clinical trials have demonstrated the efficacy of Cabenuva in maintaining viral suppression in individuals who were previously stable on an oral regimen. The ATLAS and FLAIR studies, pivotal phase 3 trials, showed that Cabenuva was as effective as continuing a daily oral therapy in maintaining viral suppression in adults with HIV-1.
The efficacy of Cabenuva is measured by its ability to maintain an undetectable viral load, which is a key indicator of successful HIV treatment. In the trials, a high percentage of participants maintained viral suppression through 48 weeks, with some trials extending to 96 weeks, indicating long-term efficacy. Additionally, Cabenuva has been found to have a favorable safety profile, with most adverse events being mild to moderate and generally manageable.
Efficacy of Sunlenca (lenacapavir)
Sunlenca, also known as lenacapavir, is a novel antiretroviral medication that has shown promise in the treatment of HIV/AIDS. It is a long-acting drug that inhibits the HIV capsid, a protein shell that encloses the viral RNA, thereby interfering with multiple stages of the HIV lifecycle. Sunlenca is designed for use in combination with other antiretroviral drugs and has shown efficacy in both treatment-naïve individuals and those with multi-drug resistant HIV.
Clinical trials have demonstrated that lenacapavir, when used in combination with other antiretrovirals, can significantly reduce viral load in individuals with HIV. The CAPELLA trial, for example, focused on heavily treatment-experienced individuals with multi-drug resistant HIV. The results indicated that a majority of participants achieved a significant reduction in viral load following treatment with lenacapavir. The drug is administered via subcutaneous injection every six months, making it a convenient option for patients who struggle with adherence to daily medication regimens. The sustained-release formulation of lenacapavir supports its long-term efficacy in maintaining viral suppression in individuals with HIV/AIDS.
Regulatory Agency Approvals
Cabenuva
Sunlenca
Access Cabenuva or Sunlenca today
If Cabenuva or Sunlenca are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us